Hui Feng, MD, PhD

Associate Professor, Pharmacology & Experimental Therapeutics

Hui Feng
617.638.4171
72 E. Concord St Silvio Conte (K)

Biography

Cancer Research: Dr. Feng is Director of the Laboratory of Zebrafish Genetics and Cancer Therapeutics. Dr. Feng’s research interests focus on identifying novel genes and pathways that are essential for MYC-related tumor transformation and progression, particularly for T-Lymphoblastic Lymphoma/Leukemia, Neuroblastoma and Breast Cancer. The research strategy of Dr. Feng’s research is to combine the analysis of human cancer cells with the genetic and imaging capacities of the zebrafish system.

Current research areas in Dr. Feng’s laboratory include:
1) To determine the molecular mechanisms underlying tumor cell intravasation and tumor progression.
2) To identify novel genes and pathways that, when mutated, delay the initiation and progression of MYC-related cancers.
3) To test the identified genes’ therapeutic potential in treating MYC-related cancers and to characterize their molecular relevance to MYC.

The long-term goal of Dr. Feng’s research is to discover novel molecular therapies to target critical components of MYC-driven oncogenic pathways, thus providing treatment alternatives that are more specific and less toxic.

Other Positions

  • Member, BU-BMC Cancer Center, Boston University
  • Graduate Faculty (Primary Mentor of Grad Students), Boston University School of Medicine, Graduate Medical Sciences
  • Member, Genome Science Institute, Boston University

Education

  • Beijing Medical University, MD
  • University of Georgia, PhD
  • Peking Union Medical College, MS

Classes Taught

  • GMSMM703
  • GMSPM843

Publications

  • Published on 5/8/2020

    Qin X, Laroche FFJ, Peerzade SAMA, Lam A, Sokolov I, Feng H. In Vivo Targeting of Xenografted Human Cancer Cells with Functionalized Fluorescent Silica Nanoparticles in Zebrafish. J Vis Exp. 2020 May 08; (159). PMID: 32449736.

    Read at: PubMed
  • Published on 4/3/2020

    Igwebuike C, Yaglom J, Huiting L, Feng H, Campbell JD, Wang Z, Havasi A, Pimentel D, Sherman MY, Borkan SC. Cross organelle stress response disruption promotes gentamicin-induced proteotoxicity. Cell Death Dis. 2020 Apr 03; 11(4):217. PMID: 32245975.

    Read at: PubMed
  • Published on 1/13/2020

    Wong CK, Lambert AW, Ozturk S, Papageorgis P, Lopez D, Shen N, Sen Z, Abdolmaleky HM, Gyorffy B, Feng H, Thiagalingam S. Targeting RICTOR Sensitizes SMAD4-Negative Colon Cancer to Irinotecan. Mol Cancer Res. 2020 03; 18(3):414-423. PMID: 31932471.

    Read at: PubMed
  • Published on 12/18/2018

    Peng B, Almeqdadi M, Laroche F, Palantavida S, Dokukin M, Roper J, Yilmaz OH, Feng H, Sokolov I. Data on ultrabright fluorescent cellulose acetate nanoparticles for imaging tumors through systemic and topical applications. Data Brief. 2019 Feb; 22:383-391. PMID: 30596135.

    Read at: PubMed
  • Published on 10/15/2018

    Su H, Hu J, Huang L, Yang Y, Thenoz M, Kuchmiy A, Hu Y, Li P, Feng H, Zhou Y, Taghon T, Van Vlierberghe P, Qing G, Chen Z, Liu H. SHQ1 regulation of RNA splicing is required for T-lymphoblastic leukemia cell survival. Nat Commun. 2018 10 15; 9(1):4281. PMID: 30323192.

    Read at: PubMed
  • Published on 7/20/2018

    Kartha VK, Alamoud KA, Sadykov K, Nguyen BC, Laroche F, Feng H, Lee J, Pai SI, Varelas X, Egloff AM, Snyder-Cappione JE, Belkina AC, Bais MV, Monti S, Kukuruzinska MA. Functional and genomic analyses reveal therapeutic potential of targeting ß-catenin/CBP activity in head and neck cancer. Genome Med. 2018 07 20; 10(1):54. PMID: 30029671.

    Read at: PubMed
  • Published on 5/7/2018

    Narasimhan S, Stanford Zulick E, Novikov O, Parks AJ, Schlezinger JJ, Wang Z, Laroche F, Feng H, Mulas F, Monti S, Sherr DH. Towards Resolving the Pro- and Anti-Tumor Effects of the Aryl Hydrocarbon Receptor. Int J Mol Sci. 2018 May 07; 19(5). PMID: 29735912.

    Read at: PubMed
  • Published on 4/25/2018

    Huiting LN, Samaha Y, Zhang GL, Roderick JE, Li B, Anderson NM, Wang YW, Wang L, Laroche F, Choi JW, Liu CT, Kelliher MA, Feng H. UFD1 contributes to MYC-mediated leukemia aggressiveness through suppression of the proapoptotic unfolded protein response. Leukemia. 2018 11; 32(11):2339-2351. PMID: 29743725.

    Read at: PubMed
  • Published on 7/26/2017

    Anderson NM, Mucka P, Kern JG, Feng H. The emerging role and targetability of the TCA cycle in cancer metabolism. Protein Cell. 2018 02; 9(2):216-237. PMID: 28748451.

    Read at: PubMed
  • Published on 7/24/2017

    Liu X, Li YS, Shinton SA, Rhodes J, Tang L, Feng H, Jette CA, Look AT, Hayakawa K, Hardy RR. Zebrafish B Cell Development without a Pre-B Cell Stage, Revealed by CD79 Fluorescence Reporter Transgenes. J Immunol. 2017 09 01; 199(5):1706-1715. PMID: 28739882.

    Read at: PubMed

View 22 more publications: View full profile at BUMC

View all profiles